Clinical Trial Update: Tipifarnib in Subjects With Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

A Phase 2 trial of tipifarnib for myelodysplastic syndromes was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: Kura Oncology, Inc. | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED | Results posted: 2024-07-31